trial
as of 2026-07-01Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
NCTId NCT03883204
at a glance
Phase 4 · Unknown
Enrollment 115 (estimated)
Sponsored by Fundación Marques de Valdecilla
Primary completion 2020-12-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Unknown
Enrollment
115 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2015-01-01
Primary completion
2020-12-01
Eligibility
ALL · 15 Years · 60 Years
Interventions & indications
Sponsors
Fundación Marques de ValdecillaLead Sponsor
Instituto de Investigación Marqués de ValdecillaCollaborator
Investigators
1
Benedicto Crespo-Facorro, ProfessorPrincipal Investigator
Sites
1 total
Santander, Spain
Facts & assertions
4 sourced
Enrollment
115
Phase
PHASE4
Primary Completion Date
2020-12-01
Status
UNKNOWN
relationships
The graph out of here
drug
drug
drug
lead_sponsor
collaborator
indication
investigator